Skip to main content
Premium Trial:

Request an Annual Quote

Xenogen Acquisition Helps Caliper Post 25-Percent Rise in Q3 Revenue

NEW YORK (GenomeWeb News) — Caliper Life Sciences today said third-quarter revenues increased 24 percent as R&D spending more than doubled and losses surged 250 percent.
Total receipts for the three months ended Sept. 30 increased to $26.5 million from $21.3 million year over year. Most of that revenue came from product sales, which brought in $18.5 million, while services brought in $6 million and licensing and contracts earned $2 million. 
The company said much of the increased revenue may be attributed to sales from Xenogen, which Caliper acquired in August
Caliper CEO said integration of the new company “is ahead of schedule and we are on track to exceed our cost and revenue synergy goals.”
R&D spending increased to $8.7 million from $4.3 million year over year.
The company said net losses increased to $13.5 million from $3.9 million in the year-ago period. Caliper said the Xenogen acquisition was the “most significant factor” fueling the increased loss.
Caliper said it had around $29.8 million in cash, cash equivalents, and marketable securities as of Sept. 30.
The company said it expects fourth-quarter revenues between $34 million and $38 million, which would be improvements of between 26 percent and 41 percent.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.